All Headlines >>
The anti-emetic, Cerenia (maropitant citrate), has gained licenses for use in puppies from as young as eight weeks of age and in cats from 16 weeks of age in the prevention and treatment of vomiting and reduction of nausea.
Cerenia is an NK-1 receptor antagonist which Pfizer says is effective against both peripheral and central emetic stimuli by acting on the final common pathway for emesis. It is, according to the company, the only NK-1 receptor antagonist licensed for dogs and cats.
Pfizer adds that in addition to the use for general emesis in puppies, Cerenia can also be used for chemotherapy-induced nausea in dogs. Studies in human oncology show that some patients receiving chemotherapy consider nausea to be more distressing than vomiting1. and the use of NK-1 receptor antagonists has shown clear benefits in the prevention of nausea and vomiting in chemotherapy-treated humans2. Cerenia tablets are also for the treatment for motion sickness in dogs aged 16 weeks or older, delivering claimed efficacy up to 93% without sedating the dog.
Kate Grocott, Product Manager for Cerenia, said: "Already successfully used in the treatment and prevention of vomiting and chemotherapy nausea in dogs, the new licence is a positive step forward for the prevention and early treatment of vomiting for puppies as young as eight weeks of age and cats from 16 weeks old. Being able to deploy Cerenia in these cases, will improve quality of life, and increases the likelihood of the animal voluntarily taking food and water thereby assisting in the recovery where there is underlying disease."
The new licence for treatment of cats with Cerenia is associated with the injectable form, while puppies may be treated with either an injection or tablets.
For further information, contact your Pfizer Animal Health account manager or call 0845 300 8034.
References
PS: Whilst you're here, take a moment to see our latest job opportunities for vet nurses.